-

DiaMedica Therapeutics to Present at the H.C. Wainwright BioConnect Conference

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021.

The recorded presentation will be available on the Investors section of the Company’s website at https://ir.diamedica.com/events-and-presentations beginning Monday, January 11th.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders. DiaMedica’s shares are listed on The Nasdaq Capital Market under the trading symbol “DMAC.”

For more information, please visit www.diamedica.com.

Contacts

Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com

Industry:

DiaMedica Therapeutics Inc.

NASDAQ:DMAC
Release Versions
English

Contacts

Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com

More News From DiaMedica Therapeutics Inc.

DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the Company will present at the 2026 Jefferies Global Healthcare Conference being held in New York on June 2-4 2026. Jefferies Global Healthcare Conference Date: Thursday, June 4, 2026 Time: 3:45 PM ET Format: Corporate Presentation If you are interested in...

DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke, preeclampsia and fetal growth restriction, today announced that enrollment in its pivotal Phase 2/3 ReMEDy2 trial of DM199 (rinvecalinase alfa) in patients with acute ischemic stroke (AIS) has reached 75% of the 200-patient threshold required to trigger the planned interim analysis. The Company reiterates its guida...

DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that its President and CEO, Rick Pauls, will participate in a fireside chat at the upcoming 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19th in New York City. Fireside Chat Details Date & Time: Tuesday, May 19, 2026 | 4:05-4:30...
Back to Newsroom